ABSORICA LD® (isotretinoin) Clinical Awareness Resource and Education C-A-R-E™ Program

ABSORICA LD (isotretinoin) Capsules—Micronized Formulation: Dosing Guide for Healthcare Professionals

PrABSORICA LD® (isotretinoin capsules) is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne. **Because of significant adverse reactions associated with its use, ABSORICA LD® should be reserved for patients where the conditions listed above are unresponsive to conventional first line therapies. ABSORICA LD® should not be substituted with other marketed formulations of isotretinoin.**

ABSORICA LD is a new micronized formulation of isotretinoin with dosing recommendations that may vary between patients. The patient's mental state, including whether or not they have a history of previous psychiatric illness must be assessed prior to beginning treatment.

ABSORICA LD is not interchangeable with any other currently available isotretinoin-containing products.

- ABSORICA LD is available in 8-, 16-, 24-, and 32-mg capsules.
- The initial dose of ABSORICA LD should be individualized according to the patient's weight and severity of the disease. In general, patients should receive ABSORICA LD at 0.4 to 0.8 mg/kg of body weight daily, taken with or without meals. It should be taken in the nearest number of whole capsules, either as a single dose or in 2 divided doses during the day, whichever is more convenient. To decrease the risk of esophageal irritation, instruct patients to take the capsules with a full glass of liquid. Do not chew or open the capsules. It should be noted that transient exacerbation of acne is occasionally seen.
- During treatment, ABSORICA LD may be adjusted according to response and/or adverse reactions, some of which may be dose-related. In exceptional instances, dosage may be adjusted up to 1.6 mg/kg depending upon individual patient response and tolerance to the drug.
- If a patient misses a dose of ABSORICA LD, it may be taken later the same day, but the patient should be instructed not to take more ABSORICA LD in 1 day than what has been prescribed. The patient should then administer the next dose on the usual scheduled dosing day. The patient should not take a double dose to make up for a missed dose.

Please refer to the ABSORICA LD Product Monograph for complete dosing information.

ABSORICA LD Daily Dosing by Body Weight

Body Weight (kg)	Total Daily Dosage (mg)[a]		
	0.4 mg/kg	0.8 mg/kg	1.6 mg/kg
40	16	32	64
50	20	40	80
60	24	48	96
70	28	56	112
80	32	64	128
90	36	72	144
100	40	80	160

Adapted from the ABSORICA LD Product Monograph.

[a]Administer in the nearest number of whole capsules, either as a single dose or in 2 divided doses.

SUN PHARMA

PrAbsorica LD®

Duration of Use:

A normal, complete course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, treatment with ABSORICA LD may be discontinued.

After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular acne, a second course of ABSORICA LD may be initiated in patients who have completed skeletal growth. The use of another course of ABSORICA LD therapy is not recommended before a 2-month waiting period because the patient's acne may continue to improve after a 15- to 20-week course of therapy. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth.

Long-term use of ABSORICA LD, even in low dosages, has not been studied, and is not recommended. The effect of long-term use of ABSORICA LD on bone loss is unknown.

For more resources:

All patient materials and physician materials can be downloaded from the C-A-R-E Program website www.AbsoricaLD.ca, or made available by contacting Sun Pharma Canada Customer Service at Med.InfoCanada@sunpharma.com, or by phone at 1-833-388-0532.

For more information:

Please consult the Product Monograph at: https://pdf.hres.ca/dpd_pm/00071353.PDF for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use.

The Product Monograph is also available by calling 1-844-924-0656.

Reference: ABSORICA LD Product Monograph. Sun Pharmaceutical Industries Limited; 22 June 2023.

REVIEWED BY PAAB

Pr Absorica LD®